title: Fluoride and casein phosphopeptide-amorphous calcium phosphate.
abstract: Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) slows the progression of caries and remineralizes enamel subsurface lesions. The aim of this study was to determine the ability of CPP-ACP to increase the incorporation of fluoride into plaque and to promote enamel remineralization in situ. Randomized, double-blind, cross-over studies involved mouthrinses and dentifrices containing CPP-ACP and fluoride. The mouthrinses were used for 60 sec, three times/day for 5 days, and supragingival plaque was collected and analyzed for F. The dentifrices were rinsed as a water slurry for 60 sec four times/day for 14 days in an in situ model. The addition of 2% CPP-ACP to the 450-ppm-F mouthrinse significantly increased the incorporation of fluoride into plaque. The dentifrice containing 2% CPP-ACP produced a level of remineralization similar to that achieved with a dentifrice containing 2800 ppm F. The dentifrice containing 2% CPP-ACP plus 1100 ppm F was superior to all other formulations.
authors: Cooperative Research Centre for Oral Health Science, School of Dental Science, Bio21 Institute, The University of Melbourne, 720 Swanston Street, Victoria 3000, Australia. e.reynolds@unimelb.edu.au
authors: E C
authors: EC
authors: Reynolds
authors: F
authors: F
authors: Cai
authors: N J
authors: NJ
authors: Cochrane
authors: P
authors: P
authors: Shen
authors: G D
authors: GD
authors: Walker
authors: M V
authors: MV
authors: Morgan
authors: C
authors: C
authors: Reynolds
mesh_terms: D000328:Adult; D001031:Apatites / Q000032:analysis; D002327:Cariostatic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002364:Caseins / Q000008:administration & dosage / Q000627:therapeutic use*; D002626:Chemistry, Pharmaceutical; D018592:Cross-Over Studies; D003743:Dental Enamel / Q000378:metabolism; D003773:Dental Plaque / Q000378:metabolism; D003802:Dentifrices / Q000627:therapeutic use; D004311:Double-Blind Method; D004338:Drug Combinations; D004577:Electron Probe Microanalysis; D005260:Female; D005459:Fluorides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009067:Mouthwashes / Q000627:therapeutic use; D010919:Placebos; D012969:Sodium Fluoride / Q000008:administration & dosage / Q000627:therapeutic use; D014089:Tooth Remineralization / Q000379:methods*
chemical_list: D001031:Apatites; D002327:Cariostatic Agents; D002364:Caseins; D003802:Dentifrices; D004338:Drug Combinations; D009067:Mouthwashes; D010919:Placebos; C447032:casein phosphopeptide-amorphous calcium phosphate nanocomplex; D012969:Sodium Fluoride; C025105:fluorapatite; D005459:Fluorides